Pure Global
PACTR201311000659400

ADAPT Phase 2

Efficacy and safety of Artemisinin-based Combination Therapies (ACTs) in malaria-infected patients taking Antiretroviral Therapies (ART) in Malawi, Moçambique and Zambia.
Liverpool School of Tropical Medicine·Not Applicable·Pan Africa Clinical Trials Registry·drugCompleted
Study focus
Disease/Condition
Infections and Infestations; Infections and Infestations
Intervention type
drug
Sponsor & location
Primary sponsor
Liverpool School of Tropical Medicine
Funder
European & Developing Countries Clinical Trials Partnership (EDCTP)
Location
Mozambique;Zambia;Malawi
Timeline & enrollment
Phase
Not Applicable
Start date
Oct 23, 2013
End date
Jun 30, 2015
Summary

Artemisin-based combination therapies (ACTs) are metabolized by liver enzymes which are induced or inhibited by antiretroviral (ARV) drugs such as efavirenz (EFV) and nevirapine (NVP). This clinical trial aims at assessing the efficacy and safety artemether-lumefantrine (AL) and dihydroartemisin-piperaquine (DHA-PPQ) in people with uncomplicated plasmodium falciparum malaria taking NVP or EFV-based Antiretroviral Therapy (ART).

ICD-10 classifications
Certain infectious and parasitic diseasesInfestation, unspecifiedOther specified infestationsOther infestationsSequelae of infectious and parasitic diseases
Data source
Registry
Pan Africa Clinical Trials Registry
Trial ID
PACTR201311000659400
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for PACTR201311000659400 through Pure Global AI's free database. This Not Applicable trial is sponsored by Liverpool School of Tropical Medicine and is currently Completed. The study focuses on Infections and Infestations; Infections and Infestations.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.